The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Open accessAbstract
Introduction Treatment options in the second-line extensive-stage SCLC (ED-SCLC) setting are limited. The PASSION study (ClinicalTrials.gov identifier: NCT03417895) was a phase 2 study of camrelizumab plus apatinib in ED-SCLC after platinum-based chemotherapy.Methods In stage I of the study, patients were randomized (1:1:1) to receive camrelizumab 200 mg every 2 weeks plus apatinib 375 mg once daily (QD), 5 days on and 2 days off, or 7 days on and 7 days off (six patients each cohort). On the basis of tolerability during the first 28-day cycle and efficacy data at stage I, one cohort was chosen to expand to 45 patients at stage II. The primary end point was objective response rate (ORR).Results From April 20, 2018 to March 12, 2019, a total of 59 patients were enrolled, with 47 patients in the QD cohort. In the QD cohort, confirmed ORR reached 34.0% (95% confidence interval: 20.9‒49.3), the median progression-free survival was 3.6 months, and the median overall survival was 8.4 months. Chemotherapy-sensitive and chemotherapy-resistant patients (defined as patients with disease relapse at ≥90 and <90 d after platinum-based chemotherapy, respectively) had comparable confirmed ORR (37.5% versus 32.3%), median progression-free survival (3.6 versus 2.7 mo), and median overall survival (9.6 versus 8.0 mo). Treatment-related adverse events of grade 3 or higher were reported in 43 of 59 patients (72.9%). Five patients (8.5%) discontinued because of treatment-related adverse events.Conclusions Camrelizumab plus apatinib exhibited potential antitumor activity in patients with both chemotherapy-sensitive and chemotherapy-resistant ED-SCLC who had failed platinum-based chemotherapy with an acceptable toxicity profile. This phase 2 data warrant further clinical studies of camrelizumab plus apatinib in SCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Combination therapies such as sintilimab plus anlotinib, sintilimab plus IBI305 (bevacizumab biosimilar), camrelizumab plus apatinib, and toripalimab plus axitinib demonstrated potent antitumor effects in multiple types of cancers [22, 114–120].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298
Self-citationKerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 2,011
Govindan, R., Page, N. C., Morgensztern, D., Read, W. L., Tierney, R. M., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,844
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H. Q., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitão, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,510
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062
Rini, B. I., Powles, T. B., Atkins, M. B., Escudier, B. J., McDermott, D. F., Suárez, C., Sergio Bracarda, A., Stadler, W. M., Donskov, F. N., Lee, J., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30723-8 · Cited by 991
Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., Liu, W., Tong, J., Liu, Y., Xu, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5995 · Cited by 975
Self-citationvon Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., CLARK, P. I., Palmer, M., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 900
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646
Qin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., Zhu, H., Fang, W. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30011-5 · Cited by 604
Self-citationEffect of cigarette smoking on major histological types of lung cancer: a meta-analysis
Khuder, S. (2001) · Lung Cancer · doi:10.1016/s0169-5002(00)00181-1 · Cited by 530
Ott, P. A., Élez, E., Hiret, S., Kim, D., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 521
Pesch, B., Kendzia, B., Gustavsson, P., Jöckel, K., Johnen, G., Pohlabeln, H., Olsson, A., Ahrens, W., Gross, I. M., Brüske, I., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27339 · Cited by 509
Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Chen, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2484 · Cited by 498
Self-citationFang, W., Yang, Y., Ma, Y., Hong, S., Lin, L., He, X., Xiong, J., Li, P., Zhao, H., Huang, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30495-9 · Cited by 491
Trigo, J. M., Subbiah, V., Besse, B., Moreno, V., López‐López, R., Sala, M. Á., Peters, S., Ponce, S., Fernández, C., Alfaro, V., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30068-1 · Cited by 489
Ardizzoni, A., Hansen, H., Dombernowsky, P., Gamucci, T., Kaplan, S., Postmus, P. E., Giaccone, G., Schaefer, B., Wanders, J., & Verweij, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2090 · Cited by 480
Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J. A., Schellens, J. H. M., Kao, S. C.-H., Miller, W. H., Delord, J., Gao, B., Planchard, D., Gottfried, M., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.109 · Cited by 417
von Pawel, J., Jotte, R. M., Spigel, D. R., O'Brien, M. E. R., Socinski, M. A., Mezger, J. M., Steins, M. B., Bosquée, L., Bubis, J. A., Nackaerts, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5392 · Cited by 352
Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C., Jia, Y., Shi, J., Zhang, L., Liu, X., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0640 · Cited by 323
Self-citationHuang, J., Xu, B., Mo, H., Zhang, W., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Yang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2439 · Cited by 201
Ou, S. I., Ziogas, A., & Zell, J. A. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819140fb · Cited by 164
Song, Y., Wu, J., Chen, X., Lin, T., Cao, J., Liu, Y., Zhao, Y., Jin, J., Huang, H., Hu, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1680 · Cited by 150
Treatment for small cell lung cancer, where are we now?-a review.
Alvarado-Luna, G., & Morales-Espinosa, D. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.13 · Cited by 142
Xuelian, C., Ma, L., Wang, X., Mo, H., Wu, D., Bo, L., Qu, D., Zhang, H., Jing, H., & Xu, B. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0172 · Cited by 68
Effect of cigarette smoking on major histological types of lung cancer in men
Khuder, S., Dayal, H. H., Mutgi, A. B., Willey, J. C., & Dayal, G. (1998) · Lung Cancer · doi:10.1016/s0169-5002(98)00068-3 · Cited by 60
Xu, Y., Huang, Z., Lu, H., Yu, X., Li, Y., Li, W., Chen, J., Chen, M., Gong, L., Chen, K., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0583-6 · Cited by 49
Self-citationLiu, X., Jiang, T., Li, W., Li, X., Zhao, C., Shi, J., Zhao, S., Jia, Y., Qiao, M., Zhang, L., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.022 · Cited by 44
Self-citationLiu, Y., Hu, X., Jiang, J., Yang, L., Zhou, S., Liu, P., Li, J., Wang, Y., Hao, X., & Shi, Y. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0391 · Cited by 24
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Cheng, Y., Han, L., Wu, L., Chen, J., Sun, H., Wen, G., Ji, Y., Dvorkin, M., Shi, J., Pan, Z., et al. (2022) · JAMA · doi:10.1001/jama.2022.16464 · Cited by 492
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 478
Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00224-8 · Cited by 430
Self-citationNew clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 225
Self-citation
Metadata
- Authors
- Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., Yang, H., Hu, Y., Zhou, J., Lin, X., Wang, L., Wang, Z., Xu, Y., Zhang, T., Shi, W., Zou, J., & Wang, J.
- Affiliations
- Zhejiang Cancer Hospital (CN)
- Peking University Cancer Hospital (CN)
- Henan Cancer Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Hunan Cancer Hospital (CN)
- Sir Run Run Shaw Hospital (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tongji University (CN)
- Chinese PLA General Hospital (CN)
- Zhejiang Taizhou Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Union Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- Corresponding author
- Wang, Jie
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 16
- Issue
- 2
- Pages
- 299-309
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3095089286
- Cited by
- 135
- References
- 39
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 35 · 2023: 22 · 2022: 30 · 2021: 19
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- camrelizumab, apatinib, extensive-stage small cell lung cancer, second-line therapy, PD-1 inhibitors, anti-angiogenic therapy, platinum-based chemotherapy, objective response rate, progression-free survival, overall survival, treatment-related adverse events
- MeSH terms
- Humans, Lung Neoplasms, Pyridines, Small Cell Lung Carcinoma, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
